Bolton Medical Recalls Stent Graft After 3 Deaths

Bolton Medical initiated a recall of its Relay Pro Thoracic Stent Graft System on April 23, 2024, citing difficulties encountered during the stent graft's release. The U.S. Food and Drug Administration (FDA) issued an alert detailing the recall, which has been linked to three fatalities. The specific nature of the release difficulties has not been fully elaborated upon in the initial reports, but the potential for adverse patient outcomes has prompted this regulatory action.

The Relay Pro Thoracic Stent Graft System is designed for endovascular repair of thoracic aortic aneurysms. These devices are critical in preventing rupture by reinforcing the weakened aortic wall. The recall signifies a significant safety concern, as a malfunctioning release mechanism could lead to improper placement, damage to the aorta, or other life-threatening complications during the surgical procedure. The company's decision to recall the product underscores the severity of the reported issues.

As of the FDA alert date, three deaths have been directly associated with the malfunctioning stent graft. This number highlights the critical need for immediate action by healthcare providers who may have the device in their inventory or have recently used it. Patients who have received the Relay Pro Thoracic Stent Graft System are advised to consult with their physicians to discuss any potential risks or concerns related to their treatment. The FDA is monitoring the situation closely to ensure patient safety and to gather further information on the scope of the problem.

The recall process involves notifying healthcare facilities and physicians about the issue and providing instructions for returning unused product. Bolton Medical is expected to work with regulatory bodies to investigate the root cause of the release mechanism failures. Further updates on the investigation and any potential corrective actions will likely be provided by the company and the FDA as more information becomes available. This event serves as a reminder of the ongoing vigilance required in the medical device industry to ensure product safety and efficacy.